{"url_path":"/sec/bctx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-027928-index.html","accession_number":"0001493152-26-027928","cik":"0001610820","ticker":"BCTX","issuer_name":"BriaCell Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-027928-index.html","primary_entity_key":"0001610820","primary_entity_name":"BriaCell Therapeutics Corp."},"word_count":260,"has_tables":true,"body_markdown":"**Item\n6. Exhibits**\n\n \n\nThe\nfollowing exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.\n\n \n\n**EXHIBIT\nINDEX**\n\n \n\n**Exhibit**\n \n**Description**\n\n31.1\n \n[Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *](ex31-1.htm)\n\n31.2\n \n[Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *](ex31-2.htm)\n\n32.1\n \n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *](ex32-1.htm)\n\n32.2\n \n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *](ex32-2.htm)\n\n101.INS\n \nInline\nXBRL Instance Document*\n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document*\n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Schema Document*\n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document*\n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Labels Linkbase Document*\n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document*\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\nFiled\nherewith.\n\n \n\n30\n\n \n\n \n\n**SIGNATURES**\n\n \n\nIn\naccordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,\nthereunto duly authorized.\n\n \n\n \n**BRIACELL\nTHERAPEUTICS CORP.**\n\n \n \n \n\nJune 9, 2026\nBy:\n*/s/\nWilliam V. Williams*\n\n \nName:\nWilliam\nV. Williams\n\n \nTitle:\nChief\nExecutive Officer\n\n \n \n(Principal\nExecutive Officer)\n\n \n \n \n\nJune 9, 2026\nBy:\n*/s/\nGadi Levin*\n\n \nName:\nGadi\nLevin\n\n \nTitle:\nChief\nFinancial Officer\n\n \n \n(Principal\nFinancial and Accounting Officer)\n\n \n\n31"}